Whole genome sequencing of Mycobacterium tuberculosis: current standards and open issues

…, P Miotto, B Ofori-Anyinam, V Dreyer… - NATURE reviews …, 2019 - nature.com
Whole genome sequencing (WGS) of Mycobacterium tuberculosis has rapidly progressed
from a research tool to a clinical application for the diagnosis and management of tuberculosis …

[HTML][HTML] MDR M. tuberculosis outbreak clone in Eswatini missed by Xpert has elevated bedaquiline resistance dated to the pre-treatment era

P Beckert, E Sanchez-Padilla, M Merker, V Dreyer… - Genome Medicine, 2020 - Springer
Background Multidrug-resistant (MDR) Mycobacterium tuberculosis complex strains not
detected by commercial molecular drug susceptibility testing (mDST) assays due to the RpoB …

[HTML][HTML] Bedaquiline and clofazimine resistance in Mycobacterium tuberculosis: an in-vitro and in-silico data analysis

…, T Cohen, J Coronel, DW Crook, V Dreyer… - The Lancet …, 2023 - thelancet.com
Background Bedaquiline is a core drug for the treatment of multidrug-resistant tuberculosis;
however, the understanding of resistance mechanisms is poor, which is hampering rapid …

[HTML][HTML] High fluoroquinolone resistance proportions among multidrug-resistant tuberculosis driven by dominant L2 Mycobacterium tuberculosis clones in the Mumbai …

V Dreyer, A Mandal, P Dev, M Merker, I Barilar… - Genome medicine, 2022 - Springer
Background Multidrug-resistant (MDR) Mycobacterium tuberculosis complex (MTBC) strains
are a serious health problem in India, also contributing to one-fourth of the global MDR …

Balancing access to BPaLM regimens and risk of resistance

…, S Gagneux, P Supply, V Dreyer… - The Lancet Infectious …, 2022 - thelancet.com
Viola Dreyer Viola Dreyer … Data presented by Philip Supply and Viola Dreyer suggest
that targeted NGS can detect resistance directly from smear-positive sputum …

Design of multidrug-resistant tuberculosis treatment regimens based on DNA sequencing

…, M Reimann, I Barilar, V Dreyer… - Clinical Infectious …, 2021 - academic.oup.com
Background Comprehensive and reliable drug susceptibility testing (DST) is urgently
needed to provide adequate treatment regimens for patients with multidrug-resistant/rifampicin-…

[HTML][HTML] Origin and Global Expansion of Mycobacterium tuberculosis Complex Lineage 3

…, M Varma-Basil, A Narang, S Ali, P Beckert, V Dreyer… - Genes, 2022 - mdpi.com
Simple Summary Tuberculosis still causes 1.5 million deaths annually and is mainly caused
by Mycobacterium tuberculosis complex strains belonging to three evolutionary modern …

[HTML][HTML] Implementation of whole genome sequencing for tuberculosis diagnostics in a low-middle income, high MDR-TB burden country

…, A Iskakova, S Ahmedov, U Antonenka, V Dreyer… - Scientific reports, 2021 - nature.com
Whole genome sequencing (WGS) is revolutionary for diagnostics of TB and its mutations
associated with drug-resistances, but its uptake in low- and middle-income countries is …

[HTML][HTML] Implementation of targeted next-generation sequencing for the diagnosis of drug-resistant tuberculosis in low-resource settings: a programmatic model …

…, AM Cabibbe, L Mhuulu, N Ruswa, V Dreyer… - Frontiers in Public …, 2023 - frontiersin.org
Targeted next-generation sequencing (tNGS) from clinical specimens has the potential to
become a comprehensive tool for routine drug-resistance (DR) prediction of Mycobacterium …

Pretomanid-resistant tuberculosis

N Koehler, S Andres, M Merker, V Dreyer… - Journal of …, 2023 - journalofinfection.com
We read with great interest the Letter by Lee and colleagues describing proteome analysis
of a Mycobacterium tuberculosis strain that caused tuberculosis (TB) relapse in a young …